PLI Schemes Boost Pharma, Bulk Drugs and Medical Devices – 26 September 2026

What happened

A PIB-based update on 26 September 2026 highlighted that Production Linked Incentive schemes of the Department of Pharmaceuticals have strengthened India’s manufacturing base in pharmaceuticals, bulk drugs and medical devices. The three schemes are PLI for Bulk Drugs, PLI for Pharmaceuticals and PLI for Medical Devices.

Key figures reported: Bulk Drugs outlay ₹6,940 crore targeting 41 critical APIs/KSMs/DIs; Pharmaceuticals outlay ₹15,000 crore with investment of about ₹46,744 crore; Medical Devices outlay ₹3,420 crore enabling domestic production of 57 unique high-end devices. Pharma PLI cumulative sales were reported around ₹4.02 lakh crore including large export share.

Background

PLI schemes reward incremental sales to build domestic capacity under Make in India / Atmanirbhar Bharat. Bulk-drug PLI specifically targets import dependence in critical starting materials such as Penicillin-G and Clavulanic Acid.

Why it matters for exams

Outlays, nodal department and API/KSM terminology are high-yield for UPSC Economy and SSC/banking GA.

Key facts for exams

• Nodal: Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers
• Bulk Drugs PLI outlay: ₹6,940 crore (41 critical APIs/KSMs/DIs)
• Pharmaceuticals PLI outlay: ₹15,000 crore; investment ~₹46,744 crore
• Medical Devices PLI outlay: ₹3,420 crore; 57 unique high-end devices
• Medical Devices incentive: 5% on incremental sales for five years (scheme design)

Practice MCQs

1. Which department implements the three pharma/medical-device PLI schemes cited in September 2026 updates?

   (A) Department of Biotechnology
   (B) Department of Pharmaceuticals
   (C) NITI Aayog
   (D) Department of Health Research only

   Answer: (B) – They are DoP schemes under Chemicals & Fertilizers.

2. PLI for Bulk Drugs primarily aims to reduce import dependence in:

   (A) Finished vaccines only
   (B) Critical APIs, KSMs and drug intermediates
   (C) Hospital beds
   (D) Ayurvedic herbs exclusively

   Answer: (B) – The scheme targets 41 critical APIs/KSMs/DIs.

3. Approximate outlay of the Pharmaceuticals PLI scheme is:

   (A) ₹1,500 crore
   (B) ₹3,420 crore
   (C) ₹15,000 crore
   (D) ₹75,000 crore

   Answer: (C) – PIB-linked summaries put Pharmaceuticals PLI at ₹15,000 crore.

Source: https://www.pib.gov.in/